On Tuesday, in the course of current trade, Shares of Verizon Communications Inc. (NYSE:VZ), gained 0.06%, and is now trading at $47.47.
The Board of Directors of Verizon Communications declared a quarterly dividend of 55 cents per outstanding share, unchanged from the previous quarter. The dividend is payable on Aug. 3, 2015, to Verizon Communications shareowners of record at the close of business on July 10, 2015.
Verizon has about 4.1 billion shares of common stock outstanding. The company made $7.8 billion in cash dividend payments in 2014.
Verizon Communications Inc., through its auxiliaries, provides communications, information, and entertainment products and services to consumers, businesses, and governmental agencies worldwide.
During an Afternoon trade, Shares of Hewlett-Packard Company (NYSE:HPQ), dipped -0.63%, and is now trading at $32.49.
Hewlett-Packard Company, confirmed that it has reached a settlement agreement with PGGM Vermogensbeheer B.V., the lead plaintiff in the securities class action arising from the impairment charge taken by HP following its acquisition of Autonomy. While HP believes the action has no merit, it is desirable and beneficial to HP and its shareholders to resolve settle the case as further litigation would be burdensome and protracted.
Under the terms of the settlement, HP’s insurance will pay $100 million to a settlement fund that will be used to compensate persons who purchased HP shares during the period from August 19, 2011 through November 20, 2012. No individual is contributing to the settlement. HP and its current and former officers, directors, and advisors will be released from any Autonomy-related securities claims as part of the settlement.
Hewlett-Packard Company, together with its auxiliaries, provides products, technologies, software, solutions, and services to individual consumers and small- and medium-sized businesses (SMBs), in addition to the government, health, and education sectors worldwide.
Finally, Eli Lilly and Company (NYSE:LLY), gained 0.83% Tuesday.
Trulicity™ 1.5 mg and 0.75 mg offered superior hemoglobin A1c (A1C) reduction contrast to Lantus® in a study of patients with type 2 diabetes and primarily enrolled from East Asia, according to new data presented by Eli Lilly and Company. The head-to-head study was presented recently at the 75th American Diabetes Association (ADA) Scientific Sessions in Boston.
“Ongoing to research our medicines beyond the initial clinical trial program is important for patients and for the ongoing study of diabetes,” said Brad Woodward, M.D., senior medical director, Lilly Diabetes. “These results reinforce the value, safety and efficacy of once-weekly Trulicity for people in need of additional treatment when diet, exercise and oral medicines are not enough to give them the blood sugar control they need.”
After 26 weeks, both doses of Trulicity were superior to Lantus in A1C reduction, and significantly more patients reached the recommended A1C target of less than 7 percent.
- A1C reductions from baseline: -1.7 percent (Trulicity 1.5 mg), -1.32 percent (Trulicity 0.75 mg), -1.15 percent (Lantus).
- Percentages of patients reaching target A1C levels (1
Patients treated with Trulicity 1.5 mg and 0.75 mg also lost an average of 1.51 kg and 0.88 kg respectively, while patients treated with Lantus gained 0.96 kg.
Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
